|Expense Ratio (net)||0.73%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||High|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Dec 16, 1985|
Broadly encouraging economic conditions, favorable tax policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
The fundamental performance goal for most investors is to outperform the S&P 500 Index, and a smart way to do this is with the best growth funds. As the common investment disclaimer reminds us, past performance is no guarantee of future results. But there’s also truth in the famous Mark Twain quote: “History doesn’t repeat itself but it often rhymes.”
Broadly encouraging economic conditions, favorable policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money.
Biotech stocks have taken off since President Trump took office. Through the end of July, the iShares Biotech ETF is up almost 19%, well ahead of broader market benchmarks. If you are thinking of investing in biotech stocks after this rally, here's what you need to know.